A New CYP2E1 Inhibitor, 12-Imidazolyl-1-dodecanol, Represents a Potential Treatment for Hepatocellular Carcinoma by Torsten Diesinger, Alfred Lautwein, Sebastian Bergler, Dominik Buckert, Christian Renz, Radovan Dvorsky, Vyacheslav Buko, Siarhei Kirko, Edith Schneider, Florian Kuchenbauer, Mukesh Kumar, Cagatay Günes, Felicitas Genze, Berthold Büchele, Thomas Simmet, Martin Haslbeck, Kai Masur, Thomas Barth, Dieter Müller-Enoch, Thomas Wirth, Thomas Haehner

“…Cytochrome P450 2E1 (CYP2E1) is a key target protein in the development of alcoholic and nonalcoholic fatty liver disease (FLD). The pathophysiological correlate is the massive production of reactive oxygen species. …”
Get full text

Rules for investigation of patients with asymptomatic elevation of serum aminotransferase activity by M. V. Mayevskaya, V. T. Ivashkin, Ye. N. German

“…Screening markers and specifying diagnostic tests are necessary to diagnose correct the majority of liver diseases – viral hepatites, alcoholic (ALD) and non-alcoholic fatty liver diseases (NAFLD), autoimmune hepatitis (AIH), Wilson diseases, primary hemochromatosis etc. …”
Get full text